<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563560</url>
  </required_header>
  <id_info>
    <org_study_id>DC850101</org_study_id>
    <nct_id>NCT03563560</nct_id>
  </id_info>
  <brief_title>A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia</brief_title>
  <acronym>AML</acronym>
  <official_title>A Phase 1 Clinical Study of DSP-2033 (Alvocidib) in Combination With Cytarabine/Mitoxantrone or Cytarabine/Daunorubicin (7+3) in Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, multi-center, phase 1 study of DSP-2033 (Alvocidib) in combination&#xD;
      with cytarabine/mitoxantrone (ACM regimen) or cytarabine/daunorubicin (A+7+3 regimen) in&#xD;
      patients with acute myeloid leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of 2 cohorts of the ACM regimen part for Japanese relapsed/refractory AML&#xD;
      patients and 1 cohort of the A+7+3 regimen part for Japanese newly diagnosed AML patients.&#xD;
      The purpose of this study are as below.&#xD;
&#xD;
        1. To evaluate the safety of DSP-2033 (Alvocidib) in combination with&#xD;
           cytarabine/mitoxantrone (ACM regimen) in Japanese patients with relapsed or refractory&#xD;
           AML and to confirm its tolerability.&#xD;
&#xD;
        2. To evaluate the safety of DSP-2033 （Alvocidib) in combination with&#xD;
           cytarabine/daunorubicin (A+7+3 regimen) in Japanese newly diagnosed AML patients and to&#xD;
           confirm its tolerability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2018</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study consists of 2 cohorts of the ACM regimen part and 1 cohort of the A+7+3 regimen part.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open labeled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety and tolerability in Japanese AML patients by CTCAE v4.0</measure>
    <time_frame>2 months</time_frame>
    <description>Safety and tolerability of DSP-2033 (Alvocidib) in combination with cytarabine/mitoxantrone (ACM regimen) in Japanese patients with relapsed or refractory AML and in combination with cytarabine/daunorubicin (A+7+3 regimen) in Japanese newly diagnosed AML patients.&#xD;
Safety and tolerability analyses:The number of subjects with treatment-related adverse events as assessed by CTCAE v4.0. The number of subjects with DLT and incidence rate during the DLT evaluation period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate peak plasma concentration (Cmax) of ACM regimen and A+7+3 regimen in Japanese</measure>
    <time_frame>14 days</time_frame>
    <description>Pharmacokinetics of individual drugs of ACM regimen in Japanese patients with relapsed or refractory AML and A+7+3 regimen in Japanese newly diagnosed AML patients.&#xD;
Pharmacokinetic analyses:Pharmacokinetic parameters of Maximum Plasma Concentration [Cmax] DSP-2033, DSP-2033 glucuronide (Alvo-G), cytarabine, mitoxantrone, and daunorubicin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate Area under the plasma concentration versus time curve (AUC) of ACM regimen and A+7+3 regimen in Japanese</measure>
    <time_frame>14 days</time_frame>
    <description>Pharmacokinetics of individual drugs of ACM regimen in Japanese patients with relapsed or refractory AML and A+7+3 regimen in Japanese newly diagnosed AML patients.&#xD;
Pharmacokinetic analyses:Pharmacokinetic parameters of Area Under the Curve [AUC] DSP-2033, DSP-2033 glucuronide (Alvo-G), cytarabine, mitoxantrone, and daunorubicin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Anti-tumor effects based on bone-marrow blasts</measure>
    <time_frame>2 months</time_frame>
    <description>Complete remission rate (CR rate)&#xD;
CR with incomplete hematologic recovery (CRi rate)&#xD;
Combined Complete remission rate (CRc rate): a total of CR rate and CRi rate&#xD;
Partial remission rate (PR rate)&#xD;
(Evaluated by 2017 European Leukemia Net AML efficacy assessment criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS) (ACM regimen part only)</measure>
    <time_frame>12 months</time_frame>
    <description>EFS of ACM regimen in Japanese patients with relapsed or refractory AML.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) (ACM regimen part only)</measure>
    <time_frame>12 months</time_frame>
    <description>OS of ACM regimen in Japanese patients with relapsed or refractory AML.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>ACM regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACM regimen is for Japanese patients with relapsed or refractory AML.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A+7+3 regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A+7+3 regimen is for Japanese newly diagnosed AML patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alvocidib</intervention_name>
    <description>ACM regimen:30 mg/60 mg, 30-minute intravenous (IV) infusion, followed 4-hour IV infusion from Day 1 to Day 3 A+7+3 regimen: recommended dose (RD), 30-minute IV infusion, followed 4-hour IV infusion from Day 1 to Day 3</description>
    <arm_group_label>A+7+3 regimen</arm_group_label>
    <arm_group_label>ACM regimen</arm_group_label>
    <other_name>DSP-2033</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>300 or 667 mg/m2/day, 72-hour continuous IV infusion starting on Day 6 (ACM regimen)</description>
    <arm_group_label>ACM regimen</arm_group_label>
    <other_name>DSP-AraC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>14 or 40 mg/m2/day, IV infusion over 1 hour to 2 hours at 12 hours after the end of DSP-AraC administration (acceptable range + 3 hours)</description>
    <arm_group_label>ACM regimen</arm_group_label>
    <other_name>DSP-MIT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>100 mg/m2/day, continuous IV infusion for 7 days from Day 5 to Day 11 (A+7+3 regimen)</description>
    <arm_group_label>A+7+3 regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicine</intervention_name>
    <description>60 mg/m2/day, 30-minute IV infusion for 3 days from Day 5 to Day 7</description>
    <arm_group_label>A+7+3 regimen</arm_group_label>
    <other_name>DSP-DNR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        [For all parts]&#xD;
&#xD;
          1. Japanese patients diagnosed with AML by the 4th edition of WHO criteria.&#xD;
&#xD;
          2. Patients aged between 20 and 64 at acquisition of informed consent.&#xD;
&#xD;
          3. Have received an adequate explanation of the objectives/contents of the clinical&#xD;
             study, anticipated therapeutic effects/pharmacology, and risks to his/her&#xD;
             understanding, and voluntarily provide written informed consent to participation in&#xD;
             the clinical study.&#xD;
&#xD;
          4. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2 at&#xD;
             entry.&#xD;
&#xD;
          5. Have a left ventricular ejection fraction (LVEF) ≥ 50% determined by echocardiography&#xD;
             or multigated acquisition (MUGA) scan within 14 days prior to entry.&#xD;
&#xD;
          6. Have an arterial oxygen saturation (SpO2) ≥ 90% within 14 days prior to entry.&#xD;
&#xD;
          7. The laboratory test within 14 days prior to entry (for multiple tests, the most recent&#xD;
             before the entry) meet the following criteria for major organ function.&#xD;
&#xD;
               1. Serum creatinine ≤ 1.5 x the upper limit of normal (ULN) of the institutional&#xD;
                  reference standard&#xD;
&#xD;
               2. AST and ALT ≤ 2 x ULN of the institutional reference standard&#xD;
&#xD;
               3. Total bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          8. Female patients of childbearing potential must have negative pregnancy test results at&#xD;
             entry.&#xD;
&#xD;
          9. Female patients or patients with partners of childbearing potential must agree to use&#xD;
             an appropriate method of contraception for a period between acquisition of informed&#xD;
             consent and 6 months (180 days) after the final dose so that patients or female&#xD;
             partners would not become pregnant.&#xD;
&#xD;
             [ACM regimen part] In addition to the inclusion criteria for all parts, patients must&#xD;
             meet the following criterion.&#xD;
&#xD;
         10. AML patients who could not attain remission after 1 or 2 cycles of potent chemotherapy&#xD;
             with anthracycline, cytarabine, and etoposide, or potent chemotherapy with&#xD;
             anthracycline and cytarabine. Or patients with 1st or 2nd recurrent AML after complete&#xD;
             remission following initial therapy.&#xD;
&#xD;
             [A+7+3 regimen part] In addition to the inclusion criteria for all parts, patients&#xD;
             must meet the following criterion&#xD;
&#xD;
         11. Treatment naive AML patients.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        [For all parts]&#xD;
&#xD;
          1. Diagnosed with acute promyelocytic leukemia (APL) (FAB classification: M3).&#xD;
&#xD;
          2. Received a transplantation such as hematopoietic stem cell transplant.&#xD;
&#xD;
          3. Have active central nervous system (CNS) leukemia.&#xD;
&#xD;
          4. Complicated by ≥ Grade 3 infection as specified in Common Terminology Criteria for&#xD;
             Adverse Events version 4.03 (CTCAE v4.03).&#xD;
&#xD;
          5. HIV antibody, HBs antigen, or HCV antibody tested positive within 90 days prior to&#xD;
             entry.&#xD;
&#xD;
          6. Have New York Heart Association (NYHA) cardiac function classification III or IV heart&#xD;
             disease or a history, ≥ Grade 3 arrhythmia, angina pectoris or abnormal&#xD;
             electrocardiogram (ECG) findings as specified in CTCAE v4.03 or a history of these&#xD;
             above.&#xD;
&#xD;
          7. Have a disease that may interfere with the study treatment, such as interstitial&#xD;
             pneumonia, pulmonary fibrosis, or active tuberculosis.&#xD;
&#xD;
          8. Complicated by uncontrolled disseminated intravascular coagulation.&#xD;
&#xD;
          9. Have other active malignancies (synchronous multiple malignancies and metachronous&#xD;
             multiple malignancies with a disease-free interval not more than 5 years. However,&#xD;
             carcinoma in situ that is determined to be cured by local treatment or lesions&#xD;
             equivalent to mucosal carcinoma are not included in active multiple malignancies.)&#xD;
&#xD;
         10. Have an uncontrolled complication.&#xD;
&#xD;
         11. Complicated by mental deficits or have a history of mental deficits. However, patients&#xD;
             who are able to comply with the study protocol can be included at the discretion of a&#xD;
             physician.&#xD;
&#xD;
         12. Complicated by varicella.&#xD;
&#xD;
         13. Received any previous treatment with DSP-2033 or other CDK inhibitors.&#xD;
&#xD;
         14. Received any investigational product or post-marketing clinical study drug within 3&#xD;
             months (90 days) prior to entry.&#xD;
&#xD;
         15. Pregnant or lactating women*)&#xD;
&#xD;
             *) If a lactating woman agrees to discontinue breast feeding between acquisition of&#xD;
             informed consent and 6 months (180 days) after the final dose, she could be included&#xD;
             in the study.&#xD;
&#xD;
         16. Patients who are determined to be inappropriate for participation in this study by the&#xD;
             investigator or subinvestigator.&#xD;
&#xD;
             [ACM regimen part] In addition to the exclusion criteria cfor all parts, patients who&#xD;
             meet any one of the following criteria 17 to 21 will be excluded from the ACM regimen&#xD;
             part.&#xD;
&#xD;
         17. Have the cumulative total exposure of anthracycline, daunorubicin-equivalent dose,&#xD;
             exceeds 360 mg/m2 (body surface area) at entry.&#xD;
&#xD;
         18. Received other leukemia treatment within 21 days prior to entry.&#xD;
&#xD;
         19. Have a history of radiation therapy on the mediastinum.&#xD;
&#xD;
         20. Have sustained ≥ Grade 2 adverse drug reaction (except alopecia) as specified in CTCAE&#xD;
             v4.03, which developed by the previous treatment.&#xD;
&#xD;
         21. Have a history of hypersensitivity against any one of cytarabine, mitoxantrone, or&#xD;
             contained excipients.&#xD;
&#xD;
             [A+7+3 regimen part] In addition to the exclusion criteria for all parts, patients who&#xD;
             meet any one of the following criteria 22 to 23 will be excluded from the A+7+3&#xD;
             regimen part.&#xD;
&#xD;
         22. Have the cumulative total exposure of anthracycline, daunorubicin-equivalent dose,&#xD;
             exceeds 100 mg/m2 (body surface area) at entry.&#xD;
&#xD;
         23. Have a history of hypersensitivity against any one of cytarabine, daunorubicin, or&#xD;
             contained excipients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fukui University Hospital</name>
      <address>
        <city>Yoshida-gun</city>
        <state>Fukui</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chugoku Central Hospital</name>
      <address>
        <city>Fukuyama</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokai University Hospital</name>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City Hospital Organization</name>
      <address>
        <city>Miyakojima-ku</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital</name>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>December 18, 2020</last_update_submitted>
  <last_update_submitted_qc>December 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Newly diagnosed AML</keyword>
  <keyword>Relapsed/refractory AML</keyword>
  <keyword>Alvocidib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

